Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease
November 07, 2013 06:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
November 06, 2013 06:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2013
November 01, 2013 08:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Announces Top-Line Results From Its TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease
October 14, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Announces Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis
September 12, 2013 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences
September 03, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference
August 27, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at the Upcoming Themes in Helminth Biology Scientific Conference
August 20, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 20, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2013
August 05, 2013 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences
August 01, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...